|
1
|
Michel CP, Bendahan D, Giannesini B, Vilmen C, Le Fur Y, Messonnier LA. Effects of hydroxyurea on skeletal muscle energetics and force production in a sickle cell disease murine model. J Appl Physiol (1985) 2023; 134:415-425. [PMID: 36603048 DOI: 10.1152/japplphysiol.00333.2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Hydroxyurea (HU) is commonly used as a treatment for patients with sickle cell disease (SCD) to enhance fetal hemoglobin production. This increased production is expected to reduce anemia (which depresses oxygen transport) and abnormal Hb content alleviating clinical symptoms such as vaso-occlusive crisis and acute chest syndrome. The effects of HU on skeletal muscle bioenergetics in vivo are still unknown. Due to the beneficial effects of HU upon oxygen delivery, improved skeletal muscle energetics and function in response to a HU treatment have been hypothesized. Muscle energetics and function were analyzed during a standardized rest-exercise-recovery protocol, using 31P-magnetic resonance spectroscopy in Townes SCD mice. Measurements were performed in three groups of mice: one group of 2-mo-old mice (SCD2m, n = 8), another one of 4-mo-old mice (SCD4m, n = 8), and a last group of 4-mo-old mice that have been treated from 2 mo of age with HU at 50 mg/kg/day (SCD4m-HU, n = 8). As compared with SCD2m mice, SCD4m mice were heavier and displayed a lower acidosis. As lower specific forces were developed by SCD4m compared with SCD2m, greater force-normalized phosphocreatine consumption and oxidative and nonoxidative costs of contraction were also reported. HU-treated mice (SCD4m-HU) displayed a significantly higher specific force production as compared with untreated mice (SCD4m), whereas muscle energetics was unchanged. Overall, our results support a beneficial effect of HU on muscle function.NEW & NOTEWORTHY Our results highlighted that force production decreases between 2 and 4 mo of age in SCD mice thereby indicating a decrease of muscle function during this period. Of interest, HU treatment seemed to blunt the observed age effect given that SCD4m-HU mice displayed a higher specific force production as compared with SCD4m mice. In that respect, HU treatment would help to maintain a higher capacity of force production during aging in SCD.
Collapse
Affiliation(s)
| | - David Bendahan
- CNRS, CRMBM, Aix-Marseille Université, Marseille, France
| | | | | | - Yann Le Fur
- CNRS, CRMBM, Aix-Marseille Université, Marseille, France
| | - Laurent A Messonnier
- Laboratoire Interuniversitaire de Biologie de la Motricité EA7424, Université Savoie Mont Blanc, Chambéry, France
| |
Collapse
|
|
2
|
Khromova NV, Fedorov AV, Ma Y, Kondratov KA, Prikhodko SS, Ignatieva EV, Artemyeva MS, Anopova AD, Neimark AE, Kostareva AA, Babenko AY, Dmitrieva RI. Regulatory Action of Plasma from Patients with Obesity and Diabetes towards Muscle Cells Differentiation and Bioenergetics Revealed by the C2C12 Cell Model and MicroRNA Analysis. Biomolecules 2021; 11:769. [PMID: 34063883 PMCID: PMC8224077 DOI: 10.3390/biom11060769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 05/12/2021] [Accepted: 05/17/2021] [Indexed: 11/17/2022] Open
Abstract
Obesity and type 2 diabetes mellitus (T2DM) are often combined and pathologically affect many tissues due to changes in circulating bioactive molecules. In this work, we evaluated the effect of blood plasma from obese (OB) patients or from obese patients comorbid with diabetes (OBD) on skeletal muscle function and metabolic state. We employed the mouse myoblasts C2C12 differentiation model to test the regulatory effect of plasma exposure at several levels: (1) cell morphology; (2) functional activity of mitochondria; (3) expression levels of several mitochondria regulators, i.e., Atgl, Pgc1b, and miR-378a-3p. Existing databases were used to computationally predict and analyze mir-378a-3p potential targets. We show that short-term exposure to OB or OBD patients' plasma is sufficient to affect C2C12 properties. In fact, the expression of genes that regulate skeletal muscle differentiation and growth was downregulated in both OB- and OBD-treated cells, maximal mitochondrial respiration rate was downregulated in the OBD group, while in the OB group, a metabolic switch to glycolysis was detected. These alterations correlated with a decrease in ATGL and Pgc1b expression in the OB group and with an increase of miR-378a-3p levels in the OBD group.
Collapse
Affiliation(s)
- Natalya V. Khromova
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Anton V. Fedorov
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Yi Ma
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Kirill A. Kondratov
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Stanislava S. Prikhodko
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Elena V. Ignatieva
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Marina S. Artemyeva
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Anna D. Anopova
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Aleksandr E. Neimark
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Anna A. Kostareva
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
- Center for Molecular Medicine, Department of Women’s and Children’s Health, Karolinska Institute, 17177 Stockholm, Sweden
| | - Alina Yu. Babenko
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| | - Renata I. Dmitrieva
- National Almazov Medical Research Centre, Institute of Molecular Biology and Genetics, 197341 Saint-Petersburg, Russia; (A.V.F.); (Y.M.); (K.A.K.); (S.S.P.); (E.V.I.); (M.S.A.); (A.D.A.); (A.E.N.); (A.A.K.); (A.Y.B.); (R.I.D.)
| |
Collapse
|